1. After the changes Austrianova made to the manufacturing process, about which we have already reported, we are back on track.
2. Mr. Waggoner and Mr. Judd will observe the culturing of the genetically altered HEK-293 cells both before and after they are encapsulated. Mr. Judd has a broad array of experience in development of cell culture media for many primary cells and cell lines and is particularly knowledgeable in the growth of HEK-293 cells. He has developed manufacturing processes, cell assays, biochemical analysis, cell culture processes and downstream recovery strategies. Although Mr. Judd has already offered advice to both PharmaCyte and Austrianova via telephonic communications, his actual on-site presence should prove to be invaluable. Mr. Judd will lend assistance in helping correct any unforeseen problems in the production process as the latest two staggered manufacturing “runs” are carried out and completed.
If they’re back on track and running staggered runs in production it sounds like they’ve sorted the problem before and after encapsulation.
Otherwise they’d say they have further optimized the manufacturing.
I think you’re reading between the lines too closely. My reading is that Judd solved the growth problem, for them and cane out to see it first hand in case there was more that could be donee if the new growth process didn’t oerform as expected.
Sounds to me like it did.
News 
Market Data 
Discover 
